AU2019260608A1 - Tricyclic Heterocycle Compounds useful as HIV integrase inhibitors - Google Patents

Tricyclic Heterocycle Compounds useful as HIV integrase inhibitors Download PDF

Info

Publication number
AU2019260608A1
AU2019260608A1 AU2019260608A AU2019260608A AU2019260608A1 AU 2019260608 A1 AU2019260608 A1 AU 2019260608A1 AU 2019260608 A AU2019260608 A AU 2019260608A AU 2019260608 A AU2019260608 A AU 2019260608A AU 2019260608 A1 AU2019260608 A1 AU 2019260608A1
Authority
AU
Australia
Prior art keywords
compound
mmol
isomer
compound int
int
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019260608A
Other languages
English (en)
Inventor
James M. Apgar
Zhiyong Hu
John A. Mccauley
Izzat T. Raheem
Valerie W. SHURTLEFF
Alan Whitehead
Tao Yu
Yonglian Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of AU2019260608A1 publication Critical patent/AU2019260608A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2019260608A 2018-04-27 2019-04-22 Tricyclic Heterocycle Compounds useful as HIV integrase inhibitors Abandoned AU2019260608A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862663377P 2018-04-27 2018-04-27
US62/663,377 2018-04-27
US201862664527P 2018-04-30 2018-04-30
US62/664,527 2018-04-30
PCT/US2019/028432 WO2019209667A1 (en) 2018-04-27 2019-04-22 Tricyclic heterocycle compounds useful as hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
AU2019260608A1 true AU2019260608A1 (en) 2020-10-29

Family

ID=68294232

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019260608A Abandoned AU2019260608A1 (en) 2018-04-27 2019-04-22 Tricyclic Heterocycle Compounds useful as HIV integrase inhibitors

Country Status (10)

Country Link
EP (1) EP3784241A4 (ko)
JP (1) JP2021522254A (ko)
KR (1) KR20210005139A (ko)
CN (1) CN112088005A (ko)
AU (1) AU2019260608A1 (ko)
BR (1) BR112020021768A2 (ko)
CA (1) CA3101180A1 (ko)
MA (1) MA52367A (ko)
MX (1) MX2020011317A (ko)
WO (1) WO2019209667A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210477A1 (es) 2018-05-31 2021-03-11 Shionogi & Co Derivado policiclico de carbamoilpiridona
EA202092923A1 (ru) 2018-05-31 2021-04-09 Сионоги Энд Ко., Лтд. Полициклическое производное пиридона
US11884683B2 (en) 2018-06-05 2024-01-30 Merck Sharp & Dohme Llc Tricyclic heterocycle compounds useful as HIV integrase inhibitors
MX2021011394A (es) 2019-03-22 2021-10-13 Gilead Sciences Inc Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico.
US11325891B2 (en) * 2019-11-26 2022-05-10 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
CN115151545A (zh) 2020-02-24 2022-10-04 吉利德科学公司 用于治疗hiv感染的四环化合物
FI4196479T3 (fi) 2021-01-19 2024-01-17 Gilead Sciences Inc Substituoituja pyridotriatsiiniyhdisteitä ja niiden käyttöjä

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281565T3 (es) * 2001-10-26 2007-10-01 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Inhibidores de la integrasa de vih de tipo dihidroxipirimidina carboxamida.
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US7902182B2 (en) * 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
US9643982B2 (en) * 2013-05-17 2017-05-09 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
WO2017113288A1 (en) * 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors

Also Published As

Publication number Publication date
MA52367A (fr) 2021-03-03
EP3784241A1 (en) 2021-03-03
JP2021522254A (ja) 2021-08-30
KR20210005139A (ko) 2021-01-13
WO2019209667A1 (en) 2019-10-31
EP3784241A4 (en) 2022-01-19
MX2020011317A (es) 2020-11-18
CA3101180A1 (en) 2019-10-31
BR112020021768A2 (pt) 2021-01-26
CN112088005A (zh) 2020-12-15

Similar Documents

Publication Publication Date Title
WO2019209667A1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
EP3303341B1 (en) Fused tricyclic heterocyclic compounds useful for treating hiv infection
EP3752144B1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
EP3377065B1 (en) Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
EP3389380B1 (en) Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
AU2016381072B2 (en) Fused Tricyclic Heterocyclic compounds as HIV integrase inhibitors
EP3330272B1 (en) Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2015095258A1 (en) Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
EA030695B1 (ru) Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
AU2017367714B2 (en) Tricyclic heterocycle compounds useful as HIV integrase inhibitors
US11884683B2 (en) Tricyclic heterocycle compounds useful as HIV integrase inhibitors
EP3229805A1 (en) Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
EP3548493A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
AU2022223241A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
US20210115044A1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period